

Example: Genomic Testing Cooperative Solid Tumor Profile

Tumor alteration	Result	Where to find on report
ALK Rearrangement/Fusion	No	p.10 listed under “Add-on RNA Fusions/Expression” however no abnormality listed in report
BRAF V600E Mutation	Yes	p.2 “Levels 2, 3 & 4”
BRAF Other Mutation	No	p.2 “Levels 2, 3 & 4”
CUL3 Mutation	No	p.10 listed under “Genes Tested for Abnormalities in coding sequence” however no abnormality listed in report
EGFR Exon 19 Deletion	No	p.1 “Detected Genomic Alterations” under “Level 1”
EGFR Exon 20 Insertion	No	p.1 “Detected Genomic Alterations” under “Level 1”
EGFR Exon 21 L858R Mutation	Yes	p.1 “Detected Genomic Alterations” under “Level 1”
EGFR Other Mutation	No	p.1 “Detected Genomic Alterations” under “Level 1”
ERBB2 (HER2) Amplification/Copy Number Gain	No	p.2 “Relevant Genes with No Alteration”
ERBB2 (HER2) Mutation	No	p.2 “Relevant Genes with No Alteration”
KEAP1 Mutation	No	p.10 listed under “Genes Tested for Abnormalities in coding sequence” however no abnormality listed in report
KRAS G12C Mutation	No	p.2 “Relevant Genes with No Alteration”
KRAS Other Mutation	No	p.2 “Relevant Genes with No Alteration”
MET Amplification/Copy Number Gain	No	p.2 “Relevant Genes with No Alteration”
MET exon 14 Skipping Mutation/Splice Site Alteration	No	p.2 “Relevant Genes with No Alteration”
MET Other Mutation	No	p.2 “Relevant Genes with No Alteration”

NFE2L2 Mutation	No	p.10 listed under “Genes Tested for Abnormalities in coding sequence” however no abnormality listed in report
NTRK1 Rearrangement/Fusion	No	p.10 listed under “Add-on RNA Fusions/Expression” however no abnormality listed in report
NTRK2 Rearrangement/Fusion	No	p.10 listed under “Add-on RNA Fusions/Expression” however no abnormality listed in report
NTRK3 Rearrangement/Fusion	No	p.10 listed under “Add-on RNA Fusions/Expression” however no abnormality listed in report
RET Rearrangement/Fusion	No	p.2 “Relevant Genes with No Alteration”
ROS1 Rearrangement/Fusion	No	p.2 “Relevant Genes with No Alteration”
STK11 Mutation	No	p.10 listed under “Genes Tested for Abnormalities in coding sequence” however no abnormality listed in report
TP53 Mutation	Yes	p.1 “Detected Genomic Alterations” under “Other” “TP53: I255S”

Solid Tumor Profile

Patient Name:		Ordered By:	
Date of Birth:		Ordering Physician:	
Gender (M/F):		Physician ID:	
Client:		Accession #:	
Case #:		Specimen Type:	
Body Site:		Specimen ID:	

Ethnicity:		Family History:	
MRN:		Indication for Testing:	
Collected Date:	Time	Reason for Referral:	Malignant Neoplasm of Lung
Received Date:	Time	Tumor Type:	Lung
Reported Date:	Time	Stage:	T2B

Test Description:

This is a next generation sequencing (NGS) test to identify molecular abnormalities in DNA of 434 genes implicated in solid tumors. Whenever possible, clinical relevance and implications of detected abnormalities are described below.

Detected Genomic Alterations

Level 1 (FDA-Approved)	Level 2 (Standard of Care)	Level 3 (Clinical Evidence)	Level 4 (Biological Relevance)	Other
EGFR : L858	TMB (high)	BRAF: V600E	PTEN: Deletion	TP53: I255S

Tumor Heterogeneity

BRAF and KIT mutations are detected in small subclones

Diagnostic Implications

EGFR Mutation | Lung cancer with EGFR mutation

FDA-Approved Therapeutics

EGFR : L858	Afatinib, Osimertinib, Gefitinib, Erlotinib
TMB*	Ipilimumab, Durvalumab, Avelumab, Atezolizumab, Nivolumab, Pembrolizumab,

* The drugs are approved, but the marker is not approved as a companion test

FDA-Approved Therapeutics in Other Tumor Types

BRAF: V600E	Dabrafenib, Trametinib, Vemurafenib, Binimetinib, Encorafenib, Cobimetinib, Tametinib
KIT: T670I	Regorafenib, Imatinib, Sunitinib

Relevant Alteration Associated with Resistance

NONE

Levels 2, 3 & 4 (Standard of Care and Clinical/Biological Evidence)

BRAF: V600E	Afatinib, Osimertinib, Gefitinib, Erlotinib
KIT: T670I	Regorafenib, Imatinib, Sunitinib, Sorafenib
TP53: I255S	NONE

Relevant Genes with No Alteration

KRAS	ROS1	ERBB2
RET	MET	Microsatellite

Results Summary

- There are mutations in the EGFR (EXON 21), BRAF, TP53, and KIT.
- Tumor mutation burden: high 14/mb (above median, but below upper third).
- The presence of EGFR mutation suggests response to EGFR inhibitors.
- The high TMB suggests possible response to immunotherapy.
- Heterogeneity is noted based on variant allele frequency and only subclones carry the BRAF and KIT mutations.

Biological Relevance of Detected Alterations

- EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplified tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer.
- Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF- α , AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors (Arteaga et. al.).
- c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from

genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.

- BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.
- TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.
- PTEN is a multi-functional tumor suppressor that is very commonly lost in human cancer. Observed in prostate cancer, glioblastoma, endometrial, lung and breast cancer to varying degrees. Up to 70% of prostate cancer patients have been observed to have loss of expression of the gene. It is a part of the PI3K/AKT/mTOR pathway and mTOR inhibitors have been relatively ineffective in treating patients with PTEN loss. New approaches using microRNAs are currently being investigated.

Drug Information

Afatinib:

A radiation sensitizing agent and an ErbB2 tyrosine kinase inhibitor.

EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer

GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [see Clinical Pharmacology and Clinical Studies].

Limitation of Use: The safety and efficacy of GILOTRIF have not been established in patients whose tumors have resistant EGFR mutations [see Clinical Studies].

Previously Treated, Metastatic Squamous NSCLC

GILOTRIF is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy [see Clinical Studies].

Osimertinib

An EGFR tyrosine kinase inhibitor.

EGFR inhibitor AZD9291. An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, AZD9291 selectively and covalently binds to and inhibits the activity of the mutant forms of EGFR, including the T790M EGFR mutant form, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed or mutated in many types of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As AZD9291 inhibits T790M, a secondarily acquired resistance mutation, this agent may have therapeutic benefits in tumors with T790M-mediated resistance. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR. (NCI Thesaurus)

First-line Treatment of EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC.

TAGRISSO is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

Gefitinib

An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.

RESSA is indicated for the first-line treatment of patients with or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Limitation of Use: Safety and efficacy of IRESSA have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution.

Erlotinib

An inhibitor of epidermal growth factor receptor tyrosine kinase.

Non-Small Cell Lung Cancer (NSCLC)

TARCEVA® is indicated for:

-The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.

Limitations of use:

Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations.

TARCEVA is not recommended for use in combination with platinum-based chemotherapy.

-Pancreatic Cancer

TARCEVA in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Iplimumab

YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for:

Treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older).

-Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.

-Treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with nivolumab.

-Treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Durvalumab

Targets PD-L1 protein; in phase 1 clinical trials (2014).

A Fc optimized monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; B7 homolog 1; B7H1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, durvalumab binds to PD-L1, thereby blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells. This may reverse T-cell inactivation and activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against PD-L1-expressing tumor cells. PD-L1, a member of the B7 protein superfamily, is overexpressed on certain tumor cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. The Fc region of durvalumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

-Urothelial Carcinoma

IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

-have disease progression during or following platinum-containing chemotherapy.

-have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

-This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.]

-Non-Small Cell Lung Cancer

IMFINZI is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Avelumab

Targets programmed cell death protein-1 ligand; has antineoplastic activity.

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.

-Metastatic Merkel Cell Carcinoma

BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [see Clinical Studies (14.1)].

-Locally Advanced or Metastatic Urothelial Carcinoma

BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who:

Have disease progression during or following platinum-containing chemotherapy

Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials

Atezolizumab

A monoclonal antibody that targets programmed death-ligand 1 (CD274 ANTIGEN) and is used to treat urothelial carcinoma, the most common type of bladder cancer.

TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

-are not eligible for cisplatin-containing chemotherapy, and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 5\%$ of the tumor area), as determined by an FDA-approved test, or

-are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status, or

-have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Nivolumab

A genetically engineered, fully human immunoglobulin G4 (IgG4) monoclonal anti programmed death-1/PD-1 protein antibody.

-Unresectable or Metastatic Melanoma

OPDIVO® as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.

OPDIVO as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO, in combination with ipilimumab, is indicated for the treatment of patients with unresectable or metastatic melanoma.

This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

-Adjuvant Treatment of Melanoma

OPDIVO is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

-Metastatic Non-Small Cell Lung Cancer

OPDIVO is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

-Advanced Renal Cell Carcinoma

OPDIVO as a single agent is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO, in combination with ipilimumab, is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

1.5 Classical Hodgkin Lymphoma

OPDIVO is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:

-autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or

-3 or more lines of systemic therapy that includes autologous HSCT.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

-Squamous Cell Carcinoma of the Head and Neck

OPDIVO is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

-Urothelial Carcinoma

OPDIVO (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

-have disease progression during or following platinum-containing chemotherapy

-have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

-Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

-OPDIVO, as a single agent, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

-OPDIVO, in combination with ipilimumab, is indicated for the treatment of adults and pediatric patients 12 years and older with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

-Hepatocellular Carcinoma

OPDIVO is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Pembrolizumab

A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.

Melanoma

KEYTRUDA® (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma.

-Non-Small Cell Lung Cancer

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) $\geq 50\%$] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

-KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS $\geq 1\%$) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

-KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous NSCLC. This indication is approved under accelerated approval based on tumor response rate and progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

-Head and Neck Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

-Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitation of Use: KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

-Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10], or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Microsatellite Instability-High Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient

-solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Limitation of Use: The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

-Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved

test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

-Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Potential Clinical Trials

Trial #	Status	Title	Disease	Drug	Sites
NCT02716311	Recruiting	Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer	Non Small Cell Lung Cancer	Drug: Afatinib, Cetuximab	Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France, Clinique de L'Europe, Amiens, France, Angers - CHU, (and 30 more...)
NCT03567642	Recruiting	A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers	Lung Cancer	Drug: Osimertinib, Platinum, Etoposide	Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States, Memorial Sloan Kettering Monmouth, Memorial Sloan Kettering Commack, Middletown, New Jersey, United States,
NCT03122717	Recruiting	Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	Non-Small Cell Lung Cancer	Drug: Gefitinib, Osimertinib	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States
NCT02804776	Recruiting	PRE-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery	Non-small Cell Lung Cancer	Drug: Gefitinib	National Cancer Centre, Singapore, Singapore
NCT03392246	Recruiting	A Phase 2 Study of Osimertinib in Combination With Selumetinib in	Non-small Cell Lung Cancer	Drug: Osimertinib, Selumetinib	Massachusetts General Hospital, Boston, Massachusetts,

		EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer			United States, Beth Israel Deaconess Medical Center, Boston, Dana, Boston, Massachusetts, United States Farber Cancer Institute, Massachusetts, United States,
NCT02803203	Recruiting	Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers	Non-small Cell Lung Cancer	Drug: osimertinib, Bevacizumab	Memoral Sloan Kettering Cancer Center
NCT03066206	Recruiting	Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Exon 20 Mutant NSCLC	Malignant Neoplasm of Respiratory and Intrathoracic Organ	Drug: Poziotinib	University of Texas MD Anderson Cancer Center
NCT02954523	Recruiting	Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations	EGFR Gene Mutation, NSCLC	Drug: Dasatinib, Osimertinib	Georgetown Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center
NCT03396185	Recruiting	Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer	EGFR Gene Mutation	Drug: Icotinib	Cancer Hospital, Chinese Academy of Medical Science
NCT03292133	Recruiting	A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer	Lung Cancer	Drug: (EGF816) Gefitinib	Massachusetts General Hospital
NCT02335944	Recruiting	Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.	Non Small Cell Lung Cancer	Drug: INC280 (EGF816)	City of Hope National Medical Center SC, H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt, Massachusetts, General Hospital Mass General, (and 19 more...)

NCT02714010	Recruiting	EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC	Non-Small Cell Lung Cancer	Drug: EGFR-TKI, Radiation: Whole brain	Sun Yat-sen University of cancer center, Guangzhou, Guangdong, China
NCT03455829	Recruiting	G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: G1T38, Osimertinib	Beverly Hills Cancer Center, St Joseph Heritage Healthcare
NCT02633189	Recruiting	Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer	Non-squamous Non-small Cell Lung Cancer	Drug: Erlotinib, Bevacizumab	Ospedale Ramazzini, Day Hospital Oncologico, Carpi, MO, Italy, Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico,
NCT02468661	Recruiting	A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification	Non-Small Cell Lung Cancer	Drug: INC280 single agent; INC280 in combination with erlotinib; Platinum/pe metrxed	Los Angeles Hematology/Oncology Medical Group, University of California Irvine Medical Center Chao Family SC, Orange, California, United States, Yale School of Medicine, New Haven, Connecticut, United States

Detailed Results

Single Nucleotide Variant (SNV)								
Gene name	Hgvsnp	Hgvsc	Aminoacids	Codons	Consequence	Allele frequency	Read depth	Predicted effect on protein
EGFR	NP_005219.2:p.Leu858Arg	NM_005228.3:c.2573T>G	L/R	cTg/cGg	missense_variant	37.8	411	deleterious (0)
TP53	NP_000537.3:p.Ile255Asn	NM_000546.5:c.764T>A	I/N	aTc/aAc	missense_variant	34.2	268	deleterious (0)
BRAF	NP_004324.2:p.Val600Glu	NM_004333.4:c.1799T>A	V/E	gTg/gAg	missense_variant	27.6	468	deleterious (0)
KIT	NP_000213.1:p.Trp557Arg	NM_000222.2:c.1669T>C	W/R	Tgg/Cgg	missense_variant	37.4	401	deleterious (0)
Copy Number Variant								
None								

Heterogeneity within the Tumor

The most dominant clone carries the STK11 mutation and KRAS mutations. SMARCA4 and TGFB2 mutations appear to be in subclones.

Methodology and Test Background

This is a next generation sequencing (NGS) test that analyzes DNA for abnormalities in 434 genes that are reported to be altered in various types of tumors. Nucleic acid is isolated from paraffin-embedded tissue. Testing is performed using massive parallel sequencing of the coding DNA of the listed genes. This includes sequencing of all the exons as well as 50 nucleotides at the 5' and 3' ends of each coding exon. Our sequencing method has a typical sensitivity of 3% for detecting common specific mutations and 5% for other mutations. Known hot spots in specific genes such as IDH1/2, NRAS, and KRAS are reported at levels of 1% and higher. Performance of the assay may vary dependent on the quantity and quality of nucleic acid, sample preparation and sample age. The assay is designed to detect significant gene amplification and deletion in addition to various single nucleotide variations (SNV) and indels.

Tested genes

Genes Tested for Abnormalities in coding sequence																
ABCB7	AURKB	C15ORF4 1	CEBPA	DICER1	FANCC	FLT3	GRIN2A	IRF2	LMO1	MSH2	NTRK1	POLE	RANBP2	SETD2	STAT4	TSC2
ABL1	AURKC	CALR	CHD2	DOT1L	FANCD2	FLT4	GRM3	IRF4	LPIN2	MSH6	NTRK2	POT1	RARA	SF3B1	STAT6	TSHR
ABL2	AXIN1	CARD11	CHD4	EED	FANCE	FOXL2	GSK3B	IRS2	LRP1B	MTOR	NTRK3	PPM1D	RB1	SLIT2	STK11	U2AF1
ACD	AXIN2	CBFB	CHEK1	EGFR	FANCF	FOXP1	GSKIP	JAGN1	LYN	MUTYH	NUP93	PPP2R1A	RBBP6	SLX4	SUFU	U2AF2
ACVR1B	AXL	CBL	CHEK2	EGLN1	FANCG	FRS2	H3F3A	JAK1	LYST	MVK	PAK3	PRDM1	RBM10	SMAD2	SUZ12	VEGFA
ADA	B2M	CBLB	CIC	ELANE	FANCI	FUBP1	HAX1	JAK2	LZTR1	MYC	PALB2	PREX2	RBM8A	SMAD3	SYK	VHL
AK2	BAP1	CBLC	CREBBP	EP300	FANCL	G6PC3	HGF	JAK3	MAGI2	MYCL	PARK2	PRKAR1A	RET	SMAD4	TAF1	WAS
AKT1	BARD1	CCND1	CRKL	EPAS1	FANCM	GABRA6	HIST1H3B	JUN	MAP2K1	MYCN	PAX5	PRKCI	RHEB	SMAD9	TAL1	WHSC1
AKT2	BCL2	CCND2	CRLF2	EPCAM	FAS	GALNT12	HNF1A	KAT6A	MAP2K2	MYD88	PBRM1	PRKDC	RHOA	SMAD9L	TBX3	WISP3
AKT3	BCL2L1	CCND3	CSF1R	EPHA3	FAT1	GATA1	HOXA11	KDM5A	MAP2K4	NBN	PDCD1LG1	PRSS1	RICTOR	SMARCA4	TCF3	WT1
ALK	BCL2L2	CCNE1	CSF3R	EPHA5	FBXW7	GATA2	HOXB13	KDM5C	MAP3K1	NF1	PDGFRA	PRSS8	RIT1	SMARCB1	TCIRG1	XPO1
AMER1	BCL6	CD274	CTC1	EPHA7	FGF10	GATA3	HRAS	KDM6A	MAP3K14	NF2	PDGFRB	PSTPIP1	RNF168	SMC1A	TERC	XRCC2
ANKRD26	BCOR	CD79A	CTCF	EPHB1	FGF14	GATA4	HSD3B1	KDR	MAPK1	NFE2L2	PDK1	PTCH1	RNF43	SMC3	TERF1	XRCC3
APC	BCORL1	CD79B	CTNNA1	ERBB2	FGF19	GATA6	HSP90AA1	KEAP1	MCL1	NFKBIA	PHF6	PTEN	ROS1	SMO	TERF2	ZBTB2
AR	BCR	CDAN1	CTNNA1	ERBB3	FGF23	GEN1	ID3	KEL	MDM2	NHP2	PIK3C2B	PTPN11	RPTOR	SNCAIP	TERF2IP	ZNF217
ARAF	BIRC3	CDC73	CUL3	ERBB4	FGF3	GF1	IDH1	KIF23	MDM4	NKX2-1	PIK3CA	QKI	RTKL1	SOCS1	TERT	ZNF703
ARFRP1	BLM	CDH1	CUX1	ERCC4	FGF4	GF11B	IDH2	KIT	MED12	NLRP3	PIK3CB	RAB27A	RUNX1	SOX10	TET2	ZRSR2
ARID1A	BMPR1A	CDK12	CXCR4	ERG	FGF6	GID4	IGF1R	KLF1	MEF2B	NME1	PIK3CG	RAC1	RUNX1T1	SOX2	TGFBR2	
ARID1B	BRAF	CDK4	CYLD	ERRF1	FGFR1	GLI1	IGF2	KLHL6	MEFV	NOP10	PIK3R1	RAD21	SBDS	SOX9	TNFAIP3	
ARID2	BRCA1	CDK6	DAXX	ESR1	FGFR2	GLI2	IKBKE	KLLN	MEN1	NOTCH1	PIK3R2	RAD50	SBF2	SPEN	TNFRSF14	
ASXL1	BRCA2	CDK8	DDR2	ETV6	FGFR3	GNA11	IKZF1	KMT2A	Merged	NOTCH2	PIM1	RAD51	SDHA	SPOP	TNFRSF1A	
ATG2B	BRD4	CDKN1A	DDX11	EXO1	FGFR4	GNA13	IKZF3	KMT2B	MET	NOTCH3	PLCG1	RAD51B	SDHB	SPTA1	TOP1	TGFBR2
ATM	BRIP1	CDKN1B	DDX41	EZH2	FH	GNAQ	IL2RG	KMT2C	MITF	NPM1	PLCG2	RAD51C	SDHC	SRC	TOP2A	
ATR	BTG1	CDKN2A	DKC1	FAM175 A	FLCN	GNAS	IL7R	KMT2D	MLH1	NRAS	PMS1	RAD51D	SDHD	SRSF2	TP53	
ATRX	BTK	CDKN2B	DNM2	FAM46C	FLI1	GPR124	INHBA	KRAS	MPL	NROB1	PMS2	RAD54L	SEC23B	STAG2	TRAF3	

* Microsatellite markers BAT25, BAT26, D2S123, D5S346, and D17S250 are included.

Add-on RNA Fusions/Expression

Fusion/Expression													
ABL1	ALK	BRAF	CREBBP	EPOR	ETV5	FGFR2	FOXO1	JAK2	MAP3K1	NOTCH1	NUP214	PCM1	PICALM
ABL2	BCL1	CBFB	CRLF2	ERG	ETV6	FGFR3	FUS	KMT2A	MECOM	NTRK1	NUP98	PDGFRA	PML
AKT3	BCL2	CBL	CSF1R	ETV1	EWSR1	FIP1L1	GLI1	KRT18P6	MYC	NTRK2	P2R78	PDGFRB	PTK2B
ALK	BCL6	CIC	EGFR	ETV4	FGFR1	FLT3	IKZF3	LYN	MYH9	NTRK3	PBX1	PD-L1	RARA

References

1. Prim N, Fore M, Mennecier B. *Rev Pneumol Clin*. 2014 Oct;70(5):279-85. doi: 10.1016/j.pneumo.2014.03.002. Epub 2014 May 27. Review. French. PMID: 24878189
2. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. *J Pharmacol Exp Ther*. 2012 Nov;343(2):342-50. doi: 10.1124/jpet.112.197756. Epub 2012 Aug 10. PMID: 22888144.
3. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D. *Lung Cancer*. 2012 Apr;76(1):123-7. doi: 10.1016/j.lungcan.2012.01.008. Epub 2012 Feb 10.
4. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Hirsh V. *Future Oncol*. 2011 Jul;7(7):817-25. doi: 10.2217/fon.11.62.
5. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Awada AH, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P. *Invest New Drugs*. 2013 Jun;31(3):734-41. doi: 10.1007/s10637-012-9880-0. Epub 2012 Nov 17.
6. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N. *Cancer Chemother Pharmacol*. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10.
7. BIBW 2992 in non-small cell lung cancer. Subramaniam DS, Hwang J. *Expert Opin Investig Drugs*. 2011 Mar;20(3):415-22. doi: 10.1517/13543784.2011.557063. Review.
8. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. *Breast Cancer Res Treat*. 2012 Jun;133(3):1057-65. doi: 10.1007/s10549-012-2003-y. Epub 2012 Mar 15.
9. Osimertinib: First Global Approval. *Drugs*. 2016 Feb;76(2):263-73. doi: 10.1007/s40265-015-0533-4. Review.
10. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. *N Engl J Med*. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
11. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH, Heo DS. *J Thorac Oncol*. 2015 Dec;10(12):1736-44. doi: 10.1097/JTO.0000000000000688.
12. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. *Mol Cancer Ther*. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4.
13. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Remon J, Planchard D. *Future Oncol*. 2015 Nov;11(22):3069-81. doi: 10.2217/fon.15.250. Epub 2015 Oct 9. Review.
14. Osimertinib making a breakthrough in lung cancer targeted therapy. Zhang H. *Onco Targets Ther*. 2016 Sep 6;9:5489-93. doi: 10.2147/OTT.S114722. eCollection 2016. Review.
15. Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment. Noonan SA, Sachs PB, Camidge DR. *J Thorac Oncol*. 2016 Dec;11(12):2253-2258. doi: 10.1016/j.jtho.2016.08.144. Epub 2016 Sep 13.
16. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. *Cancer Discov*. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.
17. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA. *Cancer Res*. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Dhillon S. *Target Oncol*. 2015 Mar;10(1):153-70. doi: 10.1007/s11523-015-0358-9. Epub 2015 Feb 1. Review.
18. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Li Q, Zhang D, Chen X, He L, Li T, Xu X, Li M. *Sci Rep*. 2015 Nov 6;5:16082. doi: 10.1038/srep16082.
19. Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells. Okon IS, Coughlan KA, Zhang M, Wang Q, Zou MH. *J Biol Chem*. 2015 Apr 3;290(14):9101-10. doi: 10.1074/jbc.M114.631580. Epub 2015 Feb 13.

20. Lovastatin overcomes gefitinib resistance through TNF- α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo. Yang SH, Lin HY, Chang VH, Chen CC, Liu YR, Wang J, Zhang K, Jiang X, Yen Y. *Oncotarget*. 2015 Sep 15;6(27):23857-73.
21. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Kobayashi H, Sato K, Niioka T, Miura H, Ito H, Miura M. *Clin Lung Cancer*. 2015 Jul;16(4):274-81. doi: 10.1016/j.clcc.2014.12.004. Epub 2014 Dec 11.
22. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. Bi Y, Deng J, Murry DJ, An G. *AAPS J*. 2016 Jan;18(1):228-38. doi: 10.1208/s12248-015-9836-3. Epub 2015 Nov 11.
23. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Deng M, Wang J, Chen Y, Zhang L, Liu D. *Anticancer Drugs*. 2015 Apr;26(4):422-7. doi: 10.1097/CAD.0000000000000202.
24. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. *Korean J Intern Med*. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.
25. Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Lee DH, Lee JS, Wang J, Hsia TC, Wang X, Kim J, Orlando M. *Cancer Res Treat*. 2015 Oct;47(4):616-29. doi: 10.4143/crt.2014.051. Epub 2014 Nov 24.
26. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators. *Lancet Oncol*. 2016 Dec;17(12):1661-1671. doi: 10.1016/S1470-2045(16)30561-7. Epub 2016 Nov 4.
27. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. Kim ST, Jang KT, Lee SJ, Jang HL, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO. *BMC Cancer*. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y.
28. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y. *Ann Oncol*. 2015 Sep;26(9):1883-9. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23.
29. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Cicenas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. *Lung Cancer*. 2016 Dec;102:30-37. doi: 10.1016/j.lungcan.2016.10.007. Epub 2016 Oct 20. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Burotto M, Manasanch EE, Wilkerson J, Fojo T. *Oncologist*. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20.
30. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. *Value Health*. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.
31. Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Zhou JG, Tian X, Wang X, Tian JH, Wang Y, Wang F, Zhang Y, Ma H. *Med Oncol*. 2015 Feb;32(2):471. doi: 10.1007/s12032-014-0471-0. Epub 2015 Jan 13. Review.
32. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. Xu JL, Jin B, Ren ZH, Lou YQ, Zhou ZR, Yang QZ, Han BH. *PLoS One*. 2015 Jul 6;10(7):e0131278. doi: 10.1371/journal.pone.0131278. eCollection 2015. Review.
33. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. *N Engl J Med*. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. Erratum in: *N Engl J Med*. 2015 Oct 15;373(16):1582.
34. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. *N Engl J Med*. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
35. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. *N Engl J Med*. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. *Ann Pharmacother*. 2015 Aug;49(8):907-37. doi: 10.1177/1060028015586218. Epub 2015 May 19. Review.

36. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. *Lancet Oncol.* 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4. Erratum in: *Lancet Oncol.* 2016 Jul;17(7):e270.
37. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Larkin J, Hodi FS, Wolchok JD. *N Engl J Med.* 2015 Sep 24;373(13):1270-1. doi: 10.1056/NEJMc1509660. No abstract available.
38. Nivolumab plus ipilimumab in advanced melanoma. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. *N Engl J Med.* 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
39. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. *J Clin Oncol.* 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.
40. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. *Lancet Oncol.* 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: *Lancet Oncol.* 2016 Jul;17(7):e270.
41. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Valsecchi ME. *N Engl J Med.* 2015 Sep 24;373(13):1270. doi: 10.1056/NEJMc1509660. No abstract available.
42. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. *N Engl J Med.* 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
43. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Spain L, Larkin J. *Expert Opin Biol Ther.* 2016;16(3):389-96. doi: 10.1517/14712598.2016.1141195. Epub 2016 Feb 1. Review.
44. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. *Lancet Oncol.* 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
45. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. *Lancet Oncol.* 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.
46. [Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Keynote 045) - AP 48/15 der AUO]. Rexer H. *Urologe A.* 2015 Sep;54(9):1287-90. doi: 10.1007/s00120-015-3934-9. German. No abstract available.
47. Pembrolizumab for the treatment of non-small-cell lung cancer. Garon EB, Rizvi NA, Hui R, Leigh N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Luceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. *N Engl J Med.* 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
48. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Ellassaiss-Schaap J, Beeram M, Drenkler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. *Clin Cancer Res.* 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.
49. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. *Lancet Oncol.* 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
50. Pembrolizumab versus Ipilimumab in Advanced Melanoma. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. *N Engl J Med.* 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

51. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csósz T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. *N Engl J Med*. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.
52. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
53. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. *Lancet*. 2016 Apr 9;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
54. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. McDermott J, Jimeno A. *Drugs Today (Barc)*. 2015 Jan;51(1):7-20. doi: 10.1358/dot.2015.51.1.2250387. Review.
55. Pembrolizumab: first global approval. Poole RM. *Drugs*. 2014 Oct;74(16):1973-1981. doi: 10.1007/s40265-014-0314-5. Review.
56. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Tan M, Quintal L. *J Clin Pharm Ther*. 2015 Oct;40(5):504-507. doi: 10.1111/jcpt.12304. Epub 2015 Jun 29. Review.
57. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Hersey P, Gowrishankar K. *Future Oncol*. 2015;11(1):133-40. doi: 10.2217/fon.14.205. Review.
58. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Sullivan RJ, Flaherty KT. *Clin Cancer Res*. 2015 Jul 1;21(13):2892-7. doi: 10.1158/1078-0432.CCR-14-3061. Epub 2015 Apr 30.
59. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhajee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. *N Engl J Med*. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
60. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. *Expert Rev Anticancer Ther*. 2015;15(9):981-93. doi: 10.1586/14737140.2015.1074862. Epub 2015 Jul 30. Review.

Electronic Signature

Maher Albitar, M.D., Pathologist - GTC Laboratories

The Technical Component Processing, Analysis and Professional Component of this test was completed at GTC Laboratories, 21 Technology Dr. #100, Irvine, CA / 92618/
Medical Director: Maher Albitar, M.D. .

The performance characteristics of this test have been determined by GTC Laboratories. This test has not been approved by the FDA. The FDA has determined such clearance or approval is not necessary. This laboratory is CLIA certified to perform high complexity clinical testing.